HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lower dose of this breast cancer drug be safer and still work?
Disease control CompletedThis study tested a lower starting dose (400 mg) of the targeted drug ribociclib combined with standard hormone therapy (letrozole or anastrozole) in 376 women with advanced hormone receptor-positive, HER2-negative breast cancer. The goal was to see if the lower dose could contro…
Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Egyptian study reveals Real-World impact of breast cancer drugs
Knowledge-focused CompletedThis study examined how well CDK4/6 inhibitors (a type of targeted therapy) work for people with advanced breast cancer in Egypt. Researchers looked at 206 patients to measure how long the drugs kept cancer from growing, side effects, and overall costs. The goal was to see if the…
Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE4 • Sponsor: Beni-Suef University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC